Challenges with advanced therapy medicinal products a

Nature Reviews Drug Discovery

9, 195-201

DOI: 10.1038/nrd3052

Citation Report

#	Article	IF	Citations
1	The Challenge of Regenerative Medicine. Hastings Center Report, 2010, 40, 24-26.	0.7	9
3	Translating Research into Clinical Scale Manufacturing of Mesenchymal Stromal Cells. Stem Cells International, 2010, 2010, 1-11.	1.2	48
4	The Cost Utility of Autologous Chondrocytes Implantation Using ChondroCelectÂ® in Symptomatic Knee Cartilage Lesions in Belgium. Pharmacoeconomics, 2010, 28, 1129-1146.	1.7	42
5	The Wire. Human Gene Therapy, 2010, 21, 662-664.	1.4	1
6	On the edge of new technologies (advanced therapies, nanomedicines). Drug Discovery Today: Technologies, 2011, 8, e21-e28.	4.0	10
7	Nanomedicine(s) under the Microscope. Molecular Pharmaceutics, 2011, 8, 2101-2141.	2.3	815
8	Clinical application of adult olfactory bulb ensheathing glia for nervous system repair. Experimental Neurology, 2011, 229, 181-194.	2.0	34
9	Production of Clinical Grade Mesenchymal Stromal Cells. , 0, , .		2
10	From Banking to International Governance: Fostering Innovation in Stem Cell Research. Stem Cells International, 2011, 2011, 1-8.	1.2	21
11	European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nature Reviews Drug Discovery, 2011, 10, 341-349.	21.5	105
12	Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues. Journal of Materials Science: Materials in Medicine, 2011, 22, 1087-1099.	1.7	2
16	EATRIS, a Vision for Translational Research in Europe. Journal of Cardiovascular Translational Research, 2011, 4, 231-237.	1.1	10
17	European Medicines Agency, CAT Secretariat & US Food and Drug Administration. Regenerative Medicine, 2011, 6, 90-96.	0.8	19
18	Regulations and guidelines governing stem cell based products: Clinical considerations. Perspectives in Clinical Research, 2011, 2, 94.	0.5	69
19	Toward a Proportionate Regulatory Framework for Gene Transfer: A Patient Group-Led Initiative. Human Gene Therapy, 2011, 22, 126-134.	1.4	5
20	Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Frontiers in Immunology, 2012, 3, 253.	2.2	79
22	An Insight on Differences in Availability and Reimbursement of Orphan Medicines Among Serbia, Bulgaria and Sweden. Biotechnology and Biotechnological Equipment, 2012, 26, 3236-3241.	0.5	15
23	Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Research and Therapy, 2012, 3, 7.	2.4	83

#	Article	IF	Citations
24	Concise Review: The Clinical Application of Mesenchymal Stem Cells for Musculoskeletal Regeneration: Current Status and Perspectives. Stem Cells Translational Medicine, 2012, 1, 237-247.	1.6	197
25	Concise Review: Cell Therapies: The Route to Widespread Adoption. Stem Cells Translational Medicine, 2012, 1, 438-447.	1.6	33
26	Autologous stem cells for personalised medicine. New Biotechnology, 2012, 29, 641-650.	2.4	30
27	Overview of Nanomedicines Regulation in the European Union. Frontiers of Nanoscience, 2012, 4, 487-507.	0.3	3
28	Regulatory Structures for Gene Therapy Medicinal Products in the European Union. Methods in Enzymology, 2012, 507, 337-354.	0.4	21
29	Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis. Frontiers in Pharmacology, 2012, 3, 12.	1.6	30
30	Clinical Development of Advanced Therapy Medicinal Products in Europe: Evidence That Regulators Must Be Proactive. Molecular Therapy, 2012, 20, 479-482.	3.7	90
31	Definition and classification of early osteoarthritis of the knee. Knee Surgery, Sports Traumatology, Arthroscopy, 2012, 20, 401-406.	2.3	211
32	Keeping an Eye on Decellularized Corneas: A Review of Methods, Characterization and Applications. Journal of Functional Biomaterials, 2013, 4, 114-161.	1.8	66
33	Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?. Stem Cells, 2013, 31, 2033-2041.	1.4	124
34	Development of a cell-based medicinal product: regulatory structures in the European Union. British Medical Bulletin, 2013, 105, 85-105.	2.7	43
35	Non-Viral Nanosystems for Gene and Small Interfering RNA Delivery to the Central Nervous System: Formulating the Solution. Journal of Pharmaceutical Sciences, 2013, 102, 3469-3484.	1.6	46
36	The Survey on Cellular and Engineered Tissue Therapies in Europe in 2011. Tissue Engineering - Part A, 2013, 20, 131108064828001.	1.6	39
37	A Comprehensive Resource on EU Regulatory Information for Investigators in Gene Therapy Clinical Research and Advanced Therapy Medicinal Products. Human Gene Therapy, 2013, 24, 12-18.	1.4	11
38	How smart do biomaterials need to be? A translational science and clinical point of view. Advanced Drug Delivery Reviews, 2013, 65, 581-603.	6.6	429
39	The risk-based approach to ATMP development â€“ Generally accepted by regulators but infrequently used by companies. Regulatory Toxicology and Pharmacology, 2013, 67, 221-225.	1.3	11
40	Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy, 2013, 15, 362-383.	0.3	57
41	Regenerative Urology Clinical Trials: An Ethical Assessment of Road Blocks and Solutions. Tissue Engineering - Part B: Reviews, 2013, 19, 41-47.	2.5	18

#	Article	IF	Citations
42	Stem Cell Treatments Around the World: Boon or Bane?. , 2013, , 365-376.		0
43	Noninvasive Real-Time Monitoring by AlamarBlueÂ®DuringIn VitroCulture of Three-Dimensional Tissue-Engineered Bone Constructs. Tissue Engineering - Part C: Methods, 2013, 19, 720-729.	1.1	33
44	Generation of mesenchymal stem cells as a medicinal product in organ transplantation. Current Opinion in Organ Transplantation, 2013, 18, 65-70.	0.8	15
45	The Evolution of Nonclinical Regulatory Science: Advanced Therapy Medicinal Products as a Paradigm. Molecular Therapy, 2013, 21, 1644-1648.	3.7	23
46	Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients. Regenerative Medicine, 2013, 8, 65-73.	0.8	19
47	European Regulatory Tools for Advanced Therapy Medicinal Products. Transfusion Medicine and Hemotherapy, 2013, 40, 409-412.	0.7	28
48	In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14026.	1.8	15
49	Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Frontiers in Cell and Developmental Biology, 2014, 2, 50.	1.8	47
50	Cell Therapy Manufacturing and Quality Control: Current Process and Regulatory Challenges. Journal of Stem Cell Research & Therapy, 2014, 04, .	0.3	18
51	Clinical Translation. , 2014, , 783-807.		0
52	Stem Cell Trials for Cardiovascular Medicine: Ethical Rationale. Tissue Engineering - Part A, 2014, 20, 2567-2574.	1.6	20
53	Pharmacoeconomic Considerations in CNS Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 375-397.	0.2	0
54	Modelâ€based cell number quantification using online singleâ€oxygen sensor data for tissue engineering perfusion bioreactors. Biotechnology and Bioengineering, 2014, 111, 1982-1992.	1.7	21
56	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. Biotechnology Advances, 2014, 32, 1396-1409.	6.0	38
57	Three-Dimensional Characterization of Tissue-Engineered Constructs by Contrast-Enhanced Nanofocus Computed Tomography. Tissue Engineering - Part C: Methods, 2014, 20, 177-187.	1.1	46
58	Challenges in the development of a reference standard and potency assay for the clinical production of RAFT tissue equivalents for the cornea. Regenerative Medicine, 2014, 9, 167-177.	0.8	13
59	A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends in Molecular Medicine, 2014, 20, 632-642.	3.5	23
60	Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy, 2014, 16, 1033-1047.	0.3	54

#	Article	IF	Citations
61	Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research. Clinical and Experimental Medicine, 2014, 14, 25-33.	1.9	21
62	Overview of Drug Delivery Devices. , 2014, , 105-134.		0
64	Manufacturing of dental pulp cell-based products from human third molars: current strategies and future investigations. Frontiers in Physiology, 2015, 6, 213.	1.3	33
65	Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy, 2015, 17, 1009-1014.	0.3	34
67	Clinical Development of Cell-Based Products. , 2015, , 351-387.		0
68	The Survey on Cellular and Engineered Tissue Therapies in Europe in 2012. Tissue Engineering - Part A, 2015, 21, 1-13.	1.6	31
69	Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells. New Biotechnology, 2015, 32, 180-190.	2.4	26
70	White spots in pharmaceutical pipelinesâ€“EMA identifies potential areas of unmet medical needs. Expert Review of Clinical Pharmacology, 2015, 8, 353-360.	1.3	7
72	Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovascular Research, 2015, 108, 4-20.	1.8	129
73	Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). Journal of Translational Medicine, 2015, 13, 160.	1.8	21
74	Are there specific translational challenges in regenerative medicine? Lessons from other fields. Regenerative Medicine, 2015, 10, 885-895.	0.8	35
75	Quantitative Validation of the Presto Blueâ„¢ Metabolic Assay for Online Monitoring of Cell Proliferation in a 3D Perfusion Bioreactor System. Tissue Engineering - Part C: Methods, 2015, 21, 519-529.	1.1	43
76	Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow. Frontiers in Cell and Developmental Biology, 2016, 4, 114.	1.8	7
77	Cell-based product classification procedure: What can be done differently to improve decisions on borderline products?. Cytotherapy, 2016, 18, 809-815.	0.3	12
78	Perinatal Gene Therapy. Pancreatic Islet Biology, 2016, , 361-402.	0.1	1
79	G-CSF prevents caspase 3 activation in Schwann cells after sciatic nerve transection, but does not improve nerve regeneration. Neuroscience, 2016, 334, 55-63.	1.1	6
80	Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrowâ€“derived multipotent mesenchymal stromal cells. Cytotherapy, 2016, 18, 1197-1208.	0.3	42
81	The New Health Bioeconomy. , 2016, , .		17

#	Article	IF	Citations
82	Regenerative pharmacology for the treatment of acute kidney injury: Skeletal muscle stem/progenitor cells for renal regeneration?. Pharmacological Research, 2016, 113, 802-807.	3.1	4
83	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. Cytotherapy, 2016, 18, 481-486.	0.3	7
84	Deciphering the EU clinical trials regulation. Nature Biotechnology, 2016, 34, 231-233.	9.4	19
85	Overview of the Development Program of a Cell-Based Medicine. , 2016, , 1-13.		0
86	Stem Cells in Skin Wound Healing: Are We There Yet?. Advances in Wound Care, 2016, 5, 164-175.	2.6	95
87	Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis. Drug Development and Industrial Pharmacy, 2017, 43, 1071-1081.	0.9	23
88	Stem Cells and Tissue Engineering. Clinics in Plastic Surgery, 2017, 44, 635-650.	0.7	56
89	Tissue Engineering of the Urethra: A Systematic Review and Meta-analysis of Preclinical and Clinical Studies. European Urology, 2017, 72, 594-606.	0.9	77
90	New Regulatory Pathways for Stem Cell-Based Therapies: Comparison and Critique of Potential Models. Stem Cells in Clinical Applications, 2017, , 173-199.	0.4	1
91	Accelerating Patientsâ€™ Access to Advanced Therapies in the EU. Molecular Therapy - Methods and Clinical Development, 2017, 7, 15-19.	1.8	19
92	Stem cell therapy clinical research: A regulatory conundrum for academia. Advanced Drug Delivery Reviews, 2017, 122, 105-114.	6.6	7
93	Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model. Frontiers in Immunology, 2017, 8, 821.	2.2	14
94	Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Frontiers in Medicine, 2017, 4, 53.	1.2	24
95	Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients. Frontiers in Medicine, 2017, 4, 56.	1.2	12
96	Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. Frontiers in Medicine, 2017, 4, 182.	1.2	41
97	Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology, 2018, 70, 31-44.	0.7	22
98	A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. Cytotherapy, 2018, 20, 769-778.	0.3	23
99	EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. Drug Discovery Today, 2018, 23, 1328-1333.	3.2	24

#	Article	IF	Citations
100	Global Regulatory Differences for Geneâ€•and Cellâ€Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation. Clinical Pharmacology and Therapeutics, 2018, 103, 120-127.	2.3	22
101	A review of the evidence for inÂvivo corneal endothelial regeneration. Survey of Ophthalmology, 2018, 63, 149-165.	1.7	97
102	Electrospun nerve guide conduits have the potential to bridge peripheral nerve injuries in vivo. Scientific Reports, 2018, 8, 16716.	1.6	51
103	Ergebnisse des AMNOG-Erstattungsbetragsverfahrens. , 2018, , 217-238.		2
104	Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products. Journal of Translational Medicine, 2018, 16, 291.	1.8	21
105	Multipotent Mesenchymal Stromal Cells From Bone Marrow for Current and Potential Clinical Applications. , 2018, , .		6
106	Gene Therapy for Cystic Fibrosis: Hurdles to Overcome for Successful Clinical Translation. , 2019, , .		0
107	Perspectives for Clinical Translation of Adipose Stromal/Stem Cells. Stem Cells International, 2019, 2019, 1-21.	1.2	73
108	Progress in the Advancement of Porous Biopolymer Scaffold: Tissue Engineering Application. Industrial & Engineering Chemistry Research, 2019, 58, 6163-6194.	1.8	133
109	Reconstruction Strategies of the Ureter and Urinary Diversion Using Tissue Engineering Approaches. Tissue Engineering - Part B: Reviews, 2019, 25, 237-248.	2.5	16
111	Corneal Endothelial Cells Over the Past Decade: Are We Missing the Mark(er)?. Translational Vision Science and Technology, 2019, 8, 13.	1.1	44
112	Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications. Drug Discovery Today, 2019, 24, 823-828.	3.2	22
113	Regenology: Time for a New Specialty?. Stem Cells Translational Medicine, 2019, 8, 4-6.	1.6	4
114	Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrowâ€“derived multipotent mesenchymal stromal cell expansion cultures. Cytotherapy, 2019, 21, 32-40.	0.3	22
115	Optimising bench science to withstand regulatory scrutiny. Pharmacological Research, 2019, 139, 491-493.	3.1	2
116	Regulatory Developments for Nonhematopoietic Stem Cell Therapeutics. , 2019, , 463-492.		1
117	Cell-based therapies in bone regeneration. , 2020, , 217-250.		0
118	Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy, 2020, 22, 592-600.	0.3	18

#	Article	IF	Citations
119	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines, 2020, 8, 708.	2.1	13
120	Gene therapy randomised clinical trials in Europe â€“ a review paper of methodology and design. Journal of Market Access & Health Policy, 2020, 8, 1847808.	0.8	2
121	An evidence map of randomised controlled trials evaluating genetic therapies. BMJ Evidence-Based Medicine, 2021, 26, 194-194.	1.7	4
122	Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products. Methods in Molecular Biology, 2020, 2286, 251-261.	0.4	5
123	Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096657.	1.4	0
124	Computational Modeling of Human Mesenchymal Stromal Cell Proliferation and Extra-Cellular Matrix Production in 3D Porous Scaffolds in a Perfusion Bioreactor: The Effect of Growth Factors. Frontiers in Bioengineering and Biotechnology, 2020, 8, 376.	2.0	11
125	Publication rates and reported results in a cohort of gene- and cell-based therapy trials. Regenerative Medicine, 2020, 15, 1215-1227.	0.8	2
126	The challenge of developing human 3D organoids into medicines. Stem Cell Research and Therapy, 2020, 11, 72.	2.4	33
127	Regulatory oversight of cell therapy in China: Governmentâ€™s efforts in patient access and therapeutic innovation. Pharmacological Research, 2020, 158, 104889.	3.1	7
128	Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines. Bone Marrow Transplantation, 2020, 55, 1229-1239.	1.3	12
129	Strategies for large-scale expansion of clinical-grade human multipotent mesenchymal stromal cells. Biochemical Engineering Journal, 2020, 159, 107601.	1.8	20
130	Gene Therapy Clinical Trials. , 2020, , 285-301.		3
131	A systematic review of economic evaluations of advanced therapy medicinal products. British Journal of Clinical Pharmacology, 2021, 87, 2428-2443.	1.1	30
132	Cognitive Knowledge Seeding Using Collective Uncertainty Shaping. Studies in Fuzziness and Soft Computing, 2021, , 31-41.	0.6	1
134	Evaluation of osteochondral-like tissues using human freeze-dried cancellous bone and chondrocyte sheets to treat osteochondral defects in rabbits. Biomaterials Science, 2021, 9, 4701-4716.	2.6	5
135	Ex Vivo Systems to Study Chondrogenic Differentiation and Cartilage Integration. Journal of Functional Morphology and Kinesiology, 2021, 6, 6.	1.1	10
136	Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. Frontiers in Cardiovascular Medicine, 2021, 8, 604434.	1.1	7
137	Sulfated polysaccharide directs therapeutic angiogenesis via endogenous VEGF secretion of macrophages. Science Advances, 2021, 7, .	4.7	65

#	Article	IF	Citations
138	Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. Pharmaceutics, 2021, 13, 347.	2.0	14
139	Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology, 2021, 73, 513-522.	0.7	14
140	New era of personalized medicine: Advanced therapy medicinal products in Europe. World Journal of Immunology, 2021, 11, 1-10.	0.5	0
141	Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells. Cells, 2021, 10, 1797.	1.8	3
142	Mesenchymal Stromal Cell Differentiation for Generating Cartilage and Bone-Like Tissues In Vitro. Cells, 2021, 10, 2165.	1.8	3
143	Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine. Cells, 2021, 10, 2140.	1.8	39
144	Introduction: specific disease areas. , 2021, , 43-262.		0
145	Bioreactor-Based Online Recovery of Human Progenitor Cells with Uncompromised Regenerative Potential: A Bone Tissue Engineering Perspective. PLoS ONE, 2015, 10, e0136875.	1.1	14
146	Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord. Histology and Histopathology, 2021, 36, 19-30.	0.5	3
147	Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Journal of Clinical Medicine Research, 2020, 12, 780-786.	0.6	24
149	Cell-Assisted Lipotransfer. Deutsches Ärzteblatt International, 2015, 112, 255-61.	0.6	12
150	Skeletal Muscle-Derived Stem Cells: Implications for Cell-Mediated Therapies. Medicina (Lithuania), 2011, 47, 469.	0.8	49
151	Regulatory challenges for the manufacture and scale-out of autologous cell therapies. Stembook, 2014, , .	0.3	20
153	- Fabrication Methods of Tissue Engineering Scaffolds. , 2014, , 406-453.		0
155	Stem Cell Therapy for Avascular Femoral Head Necrosis: From Preclinical to Clinical Study. Stem Cells in Clinical Applications, 2016, , 89-105.	0.4	0
156	Current Issues in Drug Regulation. , 2016, , 19-31.		0
157	Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. Regenerative Medicine, 2020, 15, 2015-2028.	0.8	7
158	Regulation of Stem Cell-Based Research in India in Comparison with the US, EU and other Asian Countries: Current Issues and Future Perspectives. Current Stem Cell Research and Therapy, 2020, 15, 492-508.	0.6	5

#	Article	IF	Citations
159	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Special Article: Advanced therapy medicinal products in Brazil: regulatory panorama. Hematology, Transfusion and Cell Therapy, 2021, 43, S68-S77.	0.1	0
160	Tissue Engineering and Regulatory Science. Engineering, 2022, 13, 9-12.	3.2	3
161	Neural Differentiation of Human Dental Mesenchymal Stem Cells Induced by ATRA and UDP-4: A Comparative Study. Biomolecules, 2022, 12, 218.	1.8	6
162	Mesenchymal Stem/Stromal Cells and Their Paracrine Activityâ€"Immunomodulation Mechanisms and How to Influence the Therapeutic Potential. Pharmaceutics, 2022, 14, 381.	2.0	46
163	Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number. Biology Direct, 2022, 17, 5.	1.9	1
164	Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan. Cytotherapy, 2022, 24, 557-566.	0.3	1
165	Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)â€"An Indian Perspective. Bioengineering, 2022, 9, 111.	1.6	9
167	Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. Frontiers in Oncology, 2022, 12, .	1.3	11
168	Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries. Regenerative Therapy, 2022, 20, 126-137.	1.4	6
169	The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance. Cells, 2022, 11, 2112.	1.8	3
170	Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies. Stem Cells Translational Medicine, 2022, 11, 805-813.	1.6	3
171	Is regulatory innovation fit for purpose? A case study of adaptive regulation for advanced biotherapeutics. Regulation and Governance, 0, , .	1.9	0
172	The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review. Tissue Engineering - Part B: Reviews, 2023, 29, 167-187.	2.5	10
173	Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review. Nanomaterials, 2022, 12, 3323.	1.9	18
174	Upgrading Monocytes Therapy for Critical Limb Ischemia Patient Treatment: Pre-Clinical and GMP-Validation Aspects. International Journal of Molecular Sciences, 2022, 23, 12669.	1.8	1
175	Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	2
176	Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review. Health Policy, 2022, 126, 1248-1255.	1.4	4
177	Chondrogenic differentiation of human bone marrow MSCs in osteochondral implants under kinematic mechanical load is dependent on the underlying osteo component. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	1

#	Article	IF	Citations
178	Regenerative medicine for osteonecrosis of the femoral head. Bone and Joint Research, 2023, 12, 5-8.	1.3	0
179	Immunocytochemical characterization of ex vivo cultured conjunctival explants; marker validation for the identification of squamous epithelial cells and goblet cells. Frontiers in Medicine, 0, 10, .	1.2	0
180	Tissue engineering in reconstructive urologyâ€"The current status and critical insights to set future directions-critical review. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
181	The Art of Stem Cell-Based Therapy. Advances in Experimental Medicine and Biology, 2023, , 1-12.	0.8	0
182	Illustrative Potency Assay Examples from Approved Therapies. Advances in Experimental Medicine and Biology, 2023, , 139-149.	0.8	0
183	Potency Assays: The â€˜Bugabooâ€™ of Stem Cell Therapy. Advances in Experimental Medicine and Biology, 2023, , 29-38.	0.8	0
187	Advanced Therapy Products in Brazil: Regulatory Aspects. Advances in Experimental Medicine and Biology, 2023, , 117-133.	0.8	1
188	Advanced Formulation Approaches for Emerging Therapeutic Technologies. Handbook of Experimental Pharmacology, 2023, , .	0.9	0
190	Immuntherapie mit CAR-T-Zellen: der Durchbruch in der Krebsbehandlung. , 2023, , 147-159.		0